MX2017009253A - Anticuerpos antiglicoproteina y usos de los mismos. - Google Patents

Anticuerpos antiglicoproteina y usos de los mismos.

Info

Publication number
MX2017009253A
MX2017009253A MX2017009253A MX2017009253A MX2017009253A MX 2017009253 A MX2017009253 A MX 2017009253A MX 2017009253 A MX2017009253 A MX 2017009253A MX 2017009253 A MX2017009253 A MX 2017009253A MX 2017009253 A MX2017009253 A MX 2017009253A
Authority
MX
Mexico
Prior art keywords
antibodies
methods
produced
glycoprotein
polypeptide
Prior art date
Application number
MX2017009253A
Other languages
English (en)
Inventor
W Ojala Ethan
Brown Pamela
F Lee Geoffrey
DUTZAR Benjamin
A Mulligan Jenny
S Allison Daniel
Singh Amarjeet
Original Assignee
Alder Biopharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alder Biopharmaceuticals Inc filed Critical Alder Biopharmaceuticals Inc
Publication of MX2017009253A publication Critical patent/MX2017009253A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/38—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups B01D15/265 - B01D15/36
    • B01D15/3804—Affinity chromatography
    • B01D15/3809—Affinity chromatography of the antigen-antibody type, e.g. protein A, G, L chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/14—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from fungi, algea or lichens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531—Production of immunochemical test materials
    • G01N33/532—Production of labelled immunochemicals
    • G01N33/533—Production of labelled immunochemicals with fluorescent label
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/035—Fusion polypeptide containing a localisation/targetting motif containing a signal for targeting to the external surface of a cell, e.g. to the outer membrane of Gram negative bacteria, GPI- anchored eukaryote proteins

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Analytical Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • General Engineering & Computer Science (AREA)
  • Food Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Plant Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Se describe una nueva clase de anticuerpo con especificidad por glicoproteínas. Se muestra que los anticuerpos se unen de forma específica a proteínas manosiladas, tales como proteínas producidas por hongos. Se proveen ensayos que utilizan dichos anticuerpos antiglicoproteína para monitorear la presencia de glicoproteínas en una muestra. Dichos métodos se pueden utilizar para monitorear métodos de producción y/o purificación de los polipéptidos deseados, los que se pueden usar para modificar parámetros de procesos para modificar (por ejemplo, reducir u aumentar) la cantidad de polipéptido glicosilado producido y/o presente en el producto purificado. También se proveen métodos para utilizar los anticuerpos sujeto para detectar el nivel de expresión y secreción de un polipéptido y métodos para utilizar los anticuerpos sujeto para purificar una muestra o eliminar las glicoproteínas de una muestra. En ejemplos de modalidades, el polipéptido deseado puede ser una proteína de múltiples subunidades, tal como un anticuerpo, que se puede producir en una levadura, tal como Pichia pastoris.
MX2017009253A 2015-01-16 2016-01-15 Anticuerpos antiglicoproteina y usos de los mismos. MX2017009253A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562104407P 2015-01-16 2015-01-16
PCT/US2016/013701 WO2016115521A1 (en) 2015-01-16 2016-01-15 Anti-glycoprotein antibodies and uses thereof

Publications (1)

Publication Number Publication Date
MX2017009253A true MX2017009253A (es) 2017-10-12

Family

ID=56406494

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017009253A MX2017009253A (es) 2015-01-16 2016-01-15 Anticuerpos antiglicoproteina y usos de los mismos.

Country Status (8)

Country Link
US (1) US20180142038A1 (es)
EP (1) EP3244738A4 (es)
JP (1) JP2018511300A (es)
KR (1) KR20170116050A (es)
CA (1) CA2974033A1 (es)
MX (1) MX2017009253A (es)
SG (2) SG10201906597TA (es)
WO (1) WO2016115521A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3034795A1 (en) * 2018-02-27 2019-08-27 Pfizer Inc. Antibody purification
AU2019369421A1 (en) * 2018-10-31 2021-06-03 Regeneron Pharmaceuticals, Inc. Method and system of identifying and quantifying a protein
CN113164566A (zh) * 2018-11-07 2021-07-23 第一三共株式会社 Klk5抑制性肽
CN113980092B (zh) * 2021-12-09 2024-05-14 上海药明生物技术有限公司 一种蛋白质亲和纯化方法
CN114130377A (zh) * 2021-12-14 2022-03-04 无锡创谱生物科技有限公司 一种亲和层析填料、其制备方法及用途
CN114199875B (zh) * 2022-02-18 2022-05-20 之江实验室 一种蛋白质多聚体是否可作为力缓冲剂的判断方法及装置

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7117096B2 (en) * 2001-04-17 2006-10-03 Abmaxis, Inc. Structure-based selection and affinity maturation of antibody library
US7431927B2 (en) * 2005-03-24 2008-10-07 Epitomics, Inc. TNFα-neutralizing antibodies
CA2623197A1 (en) * 2005-09-22 2007-03-29 Prosci Incorporated Glycosylated polypeptides produced in yeast mutants and methods of use thereof
CN103992405B (zh) * 2008-03-26 2016-08-17 宜康公司 抗-vegf抗体
US8399625B1 (en) * 2009-06-25 2013-03-19 ESBATech, an Alcon Biomedical Research Unit, LLC Acceptor framework for CDR grafting
CN105392883A (zh) * 2013-03-15 2016-03-09 格里科比亚有限公司 聚唾液酸、血型抗原以及糖蛋白表达

Also Published As

Publication number Publication date
EP3244738A1 (en) 2017-11-22
WO2016115521A1 (en) 2016-07-21
JP2018511300A (ja) 2018-04-26
KR20170116050A (ko) 2017-10-18
US20180142038A1 (en) 2018-05-24
SG11201705748SA (en) 2017-08-30
SG10201906597TA (en) 2019-08-27
EP3244738A4 (en) 2018-12-05
CA2974033A1 (en) 2016-07-21

Similar Documents

Publication Publication Date Title
MX2017009253A (es) Anticuerpos antiglicoproteina y usos de los mismos.
MX353144B (es) Proteinas que contienen fc de anticuerpos heterodimericos y metodos para produccion de las mismas.
SG10201909806SA (en) Production of t cell retargeting hetero-dimeric immunoglobulins
RU2018108836A (ru) ВАРИАНТЫ Fc И СПОСОБЫ ИХ ПОЛУЧЕНИЯ
EA201300048A1 (ru) Система экспрессии гетерологичных и гомологичных целлюлаз
EA201070987A1 (ru) Очищенные гибридные белки иммуноглобулина и способы их очищения
SG10201902850TA (en) Human-derived anti-dipeptide repeats (dprs) antibody
EA201590994A1 (ru) Способ увеличения гидродинамического объема полипептида путем присоединения карбоксиконцевого пептида гонадотропина
WO2015013388A3 (en) Anti-galectin-1 monoclonal antibodies and fragments thereof
SG10201807572PA (en) Robust antibody purification
MX2018012550A (es) Composiciones y metodos para la deteccion de proteinas de celulas huesped.
RU2015129656A (ru) Гуманизированное моноклональное антитело, специфичное к синдекану-1
MX2020000288A (es) Cromatografia.
EA201691548A1 (ru) Экспрессирующие конструкции и способы для отбора клеток-хозяев, экспрессирующих полипептиды
TR201907379T4 (tr) Yeni anti-insan PAI-1 antikoru.
NZ631116A (en) Process for preparing apolipoprotein a-i (apo a-i)
EA028913B9 (ru) Получение антител высокой чистоты в pichia pastoris
EA201892231A1 (ru) Способ очистки белка
EA201690271A1 (ru) Конструкции для экспрессии и способы экспрессии полипептидов в клетках эукариот
ZA202203400B (en) Hydrophobic interaction chromatography-coupled native mass spectrometry for antibody analysis
EP2647609A3 (de) Glutaminreiche Peptide als Luftporenbildner in Baustoffmassen
WO2018069640A3 (fr) Procédé de diagnostic/détermination de l'efficacité de traitement de la dépression
ZA202002083B (en) Antibody purification
MX2016002188A (es) Composición farmacéutica de proteínas híbridas recombinantes capaces de generar anticuerpos neutralizantes en contra del veneno de alacranes.
EP2708555A3 (en) Polyclonal antibodies to cloned fungal polypeptide targets